Dendritic Cells Pre-Pulsed with Wilms' Tumor 1 in Optimized Culture for Cancer Vaccination.
Wilms’ tumor 1
cell-based drug delivery
dendritic cells
tumor-associated antigens
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
28 Mar 2020
28 Mar 2020
Historique:
received:
31
01
2020
revised:
23
03
2020
accepted:
25
03
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
2
4
2020
Statut:
epublish
Résumé
With recent advances in cancer vaccination therapy targeting tumor-associated antigens (TAAs), dendritic cells (DCs) are considered to play a central role as a cell-based drug delivery system in the bioactive immune environment. Ex vivo generation of monocyte-derived DCs has been conventionally applied in adherent manufacturing systems with separate loading of TAAs before clinical use. We developed DCs pre-pulsed with Wilms' tumor (WT1) peptides in low-adhesion culture maturation (WT1-DCs). Quality tests (viability, phenotype, and functions) of WT1-DCs were performed for process validation, and findings were compared with those for conventional DCs (cDCs). In comparative analyses, WT1-DCs showed an increase in viability and recovery of the DC/monocyte ratio, displaying lower levels of IL-10 (an immune suppressive cytokine) and a similar antigen-presenting ability in an in vitro cytotoxic T lymphocytes (CTLs) assay with cytomegalovirus, despite lower levels of CD80 and PD-L2. A clinical study revealed that WT1-specific CTLs (WT1-CTLs) were detected upon using the WT1-DCs vaccine in patients with cancer. A DC vaccine containing TAAs produced under an optimized manufacturing protocol is a potentially promising cell-based drug delivery system to induce acquired immunity.
Identifiants
pubmed: 32231023
pii: pharmaceutics12040305
doi: 10.3390/pharmaceutics12040305
pmc: PMC7238244
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Vaccines (Basel). 2019 Sep 19;7(3):
pubmed: 31546936
Hum Vaccin Immunother. 2014;10(11):3175-8
pubmed: 25483658
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Scand J Immunol. 2015 Jan;81(1):56-65
pubmed: 25376441
J Immunol. 2008 Sep 1;181(5):3108-15
pubmed: 18713981
J Immunol. 2004 Mar 15;172(6):3712-8
pubmed: 15004175
Blood. 2010 Nov 25;116(22):4501-11
pubmed: 20682852
Curr Top Microbiol Immunol. 2009;333:369-93
pubmed: 19768415
J Natl Cancer Inst. 2003 Feb 19;95(4):316-26
pubmed: 12591988
J Immunother. 2006 Mar-Apr;29(2):143-50
pubmed: 16531815
J Immunol. 1997 Jun 15;158(12):5619-26
pubmed: 9190909
Vaccine. 2001 Mar 21;19(17-19):2666-72
pubmed: 11257407
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643231
Nat Med. 2004 May;10(5):475-80
pubmed: 15122249
Cytotherapy. 2015 Mar;17(3):330-5
pubmed: 25484308
Anticancer Res. 2004 Sep-Oct;24(5C):3295-301
pubmed: 15515424
Immunol Rev. 2008 Dec;226:205-18
pubmed: 19161426
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Regen Ther. 2019 May 10;12:66-73
pubmed: 31890768
Cancer Immunol Immunother. 2014 Aug;63(8):797-806
pubmed: 24777613
J Neurosurg. 2015 Oct;123(4):989-97
pubmed: 26252465
J Immunol. 2003 Feb 1;170(3):1257-66
pubmed: 12538684
Clin Cancer Res. 2014 Aug 15;20(16):4228-39
pubmed: 25056373
J Immunother. 2008 Sep;31(7):620-32
pubmed: 18600182
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Vis Exp. 2013 Aug 01;(78):
pubmed: 23928481
J Immunol. 2004 Apr 15;172(8):4733-43
pubmed: 15067049
Cytotherapy. 2005;7(4):374-84
pubmed: 16162460
Vaccines (Basel). 2015 Dec 11;3(4):1004-18
pubmed: 26690485
J Clin Oncol. 2013 Dec 1;31(34):4311-8
pubmed: 24145345
Eur J Immunol. 2013 Apr;43(4):989-1000
pubmed: 23436617
Immunity. 2006 May;24(5):563-74
pubmed: 16713974
Mol Med Rep. 2017 Nov;16(5):6787-6793
pubmed: 28901417
Clin Cancer Res. 2009 Sep 1;15(17):5323-37
pubmed: 19723653
World Neurosurg. 2012 May-Jun;77(5-6):736-44
pubmed: 22120301
Br J Cancer. 2013 Sep 17;109(6):1488-97
pubmed: 23989944
Cancer Res. 2003 Jul 15;63(14):4112-8
pubmed: 12874015
Cell Signal. 2010 Oct;22(10):1397-405
pubmed: 20363321
Nat Med. 2013 Apr;19(4):465-72
pubmed: 23455713
Tuberculosis (Edinb). 2011 Jan;91(1):36-46
pubmed: 21147037
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
Cancer Immunol Immunother. 2016 Sep;65(9):1099-111
pubmed: 27448677
J Immunol Methods. 2000 Nov 1;245(1-2):15-29
pubmed: 11042280
Cancer Sci. 2003 Dec;94(12):1091-8
pubmed: 14662025
J Immunol. 2003 Nov 15;171(10):4984-9
pubmed: 14607893
Curr Opin Pharmacol. 2019 Aug;47:20-26
pubmed: 30831470
Biomedicines. 2015 Dec 04;3(4):304-315
pubmed: 28536414
Anticancer Res. 2018 Apr;38(4):2217-2225
pubmed: 29599342
Annu Rev Immunol. 2012;30:1-22
pubmed: 22136168
Ann N Y Acad Sci. 2018 Apr;1417(1):104-115
pubmed: 29566262
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846